Send to

Choose Destination
Vaccine. 2009 Feb 18;27(8):1141-4. doi: 10.1016/j.vaccine.2008.12.022. Epub 2009 Jan 9.

Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.

Author information

Laboratoire des Bactéries Lactiques et Immunité des Muqueuses, Institut Fédératif de Recherche 142, Institut Pasteur de Lille, Lille F-59021, France.


Herein, we sought to evaluate the potential of a recombinant Lactococcus lactis strain secreting the Yersinia pseudotuberculosis low-calcium response V (LcrV) antigen for mucosal vaccination against Yersinia infections. We showed that the recombinant strain induced specific systemic and mucosal antibody and cellular immune responses after intranasal immunization and protected mice against both oral and systemic Y. pseudotuberculosis infections. This constitutes the first proof of principle for a novel anti-Yersinia mucosal vaccination strategy using recombinant lactic acid bacteria.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center